The role of co-factors in the progression from human papillomavirus infection to cervical cancer
- PMID: 23146688
- PMCID: PMC4627848
- DOI: 10.1016/j.ygyno.2012.11.003
The role of co-factors in the progression from human papillomavirus infection to cervical cancer
Abstract
Objective: Co-factors for cervical cancer, including oral contraceptive (OC) use, smoking and multiparity have been identified; however, the stage at which they act in cervical carcinogenesis is not clear. We compared established risk factors among women with CIN2 and CIN3 to evaluate the heterogeneity of these factors in precancer and also assessed their role during cervical carcinogenesis.
Methods: The current analysis included 2783 women with various stages of cervical disease who were enrolled in the Study to Understand Cervical Cancer Early Endpoints and Determinants (SUCCEED) and the Biopsy Study. Associations of co-factors within cervical precancer and at different stages of cervical carcinogenesis were estimated using logistic regression.
Results: Long-term OC use (10+years vs. never: OR=2.42, 95% CI: [1.13-5.15]), multiparity (3+ births vs. nulliparous: OR=1.54 [1.04-2.28]), smoking (ever vs. never: OR=1.95 [1.48-2.58]), and no Pap test in the previous five years (2.05 [1.32-3.17]) were positively associated with CIN3 compared to CIN2. We observed that long-term OC use, parity and smoking were associated with an increased risk of CIN3 compared to <CIN2 (1.97 [1.12-3.46]; 2.23 [1.59-3.11]; 2.60 [2.04-3.30], respectively), whereas associations were not significantly different (OC use, parity) or showed decreased risk (smoking) when comparing cancer to CIN3.
Conclusions: Differences in established risk factors suggest that CIN3 is a more specific definition of precancer than CIN2. Hormonally-related factors and smoking play a role in the transition from human papillomavirus infection to precancer.
Published by Elsevier Inc.
Conflict of interest statement
The authors declare that there are no conflicts of interest.
Similar articles
-
Human papillomavirus cofactors by disease progression and human papillomavirus types in the study to understand cervical cancer early endpoints and determinants.Cancer Epidemiol Biomarkers Prev. 2009 Jan;18(1):113-20. doi: 10.1158/1055-9965.EPI-08-0591. Cancer Epidemiol Biomarkers Prev. 2009. PMID: 19124488 Free PMC article.
-
Covariates of high-risk human papillomavirus (HPV) infections are distinct for incident CIN1, CIN2 and CIN3 as disclosed by competing-risks regression models.Eur J Gynaecol Oncol. 2012;33(1):5-14. Eur J Gynaecol Oncol. 2012. PMID: 22439398
-
Hormonal contraceptive use, pregnancy and parity, and the risk of cervical intraepithelial neoplasia 3 among oncogenic HPV DNA-positive women with equivocal or mildly abnormal cytology.Int J Cancer. 2005 Dec 20;117(6):1007-12. doi: 10.1002/ijc.21279. Int J Cancer. 2005. PMID: 15986443 Clinical Trial.
-
The epidemiology of human papillomavirus infection and cervical cancer.Dis Markers. 2007;23(4):213-27. doi: 10.1155/2007/914823. Dis Markers. 2007. PMID: 17627057 Free PMC article. Review.
-
Cumulative risk of cervical intraepithelial neoplasia for women with normal cytology but positive for human papillomavirus: Systematic review and meta-analysis.Int J Cancer. 2020 Nov 15;147(10):2695-2707. doi: 10.1002/ijc.33035. Epub 2020 May 26. Int J Cancer. 2020. PMID: 32363604
Cited by
-
Histopathological profile of cervical punch biopsies and risk factors associated with high-grade cervical precancerous lesions and cancer in northwest Ethiopia.PLoS One. 2022 Sep 12;17(9):e0274466. doi: 10.1371/journal.pone.0274466. eCollection 2022. PLoS One. 2022. PMID: 36094938 Free PMC article.
-
Current Gaps in Ovarian Cancer Epidemiology: The Need for New Population-Based Research.J Natl Cancer Inst. 2017 Oct 1;109(10):djx144. doi: 10.1093/jnci/djx144. J Natl Cancer Inst. 2017. PMID: 29117355 Free PMC article. Review.
-
Barriers to the Cervical Cancer Screening by CPC-28 Questionnaire: A Pilot Study.Arch Clin Biomed Res. 2022;6(5):764-770. doi: 10.26502/acbr.50170289. Epub 2022 Sep 20. Arch Clin Biomed Res. 2022. PMID: 36311161 Free PMC article.
-
Smoking cessation strategy in the national cervical cancer screening program (SUCCESS): study protocol for a pragmatic cluster randomised trial and process evaluation in Dutch general practice.BMJ Open. 2022 Apr 4;12(4):e055812. doi: 10.1136/bmjopen-2021-055812. BMJ Open. 2022. PMID: 35379626 Free PMC article.
-
Molecular Insights into HR-HPV and HCMV Co-Presence in Cervical Cancer Development.Cancers (Basel). 2025 Feb 8;17(4):582. doi: 10.3390/cancers17040582. Cancers (Basel). 2025. PMID: 40002177 Free PMC article. Review.
References
-
- Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S. Human papillomavirus and cervical cancer. The Lancet. 2007;370:890–907. - PubMed
-
- Appleby P, Beral V, Berrington de Gonzalez A, Colin D, Franceschi S, Goodhill A, et al. Cervical cancer and hormonal contraceptives: collaborative reanalysis of individual data for 16,573 women with cervical cancer and 35,509 women without cervical cancer from 24 epidemiological studies. Lancet. 2007;370:1609–1621. - PubMed
-
- Appleby P, Beral V, Berrington de Gonzalez A, Colin D, Franceschi S, Goodill A, et al. Carcinoma of the cervix and tobacco smoking: collaborative reanalysis of individual data on 13,541 women with carcinoma of the cervix and 23,017 women without carcinoma of the cervix from 23 epidemiological studies. Int J Cancer. 2006;118:1481–1495. - PubMed
-
- International Collaboration of Epidemiological Studies of Cervical C. Cervical carcinoma and reproductive factors: Collaborative reanalysis of individual data on 16,563 women with cervical carcinoma and 33,542 women without cervical carcinoma from 25 epidemiological studies. International Journal of Cancer. 2006;119:1108–1124. - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials